Sage Bionetworks Announces Oncology Research Partnership with Pfizer
News Jan 18, 2010
Sage Bionetworks has announced a new research partnership with Pfizer, Inc. to build, analyze and exploit advanced network models of cancer.
Pfizer will provide research funding to Sage to analyze large, globally coherent datasets from Pfizer, Sage and the public domain. Through innovative network biology analysis Sage will use the genetic, molecular and clinical information to create predictive computational disease models. These models will help identify therapeutic targets for oncology drug development as well as aid in evaluating the efficacy and safety of drug development candidates.
“We continue to implement our partnering strategy as part of our larger mission to build a Commons where users can exploit the full potential of network analysis across multiple complex datasets.”
“Our collaboration with Pfizer will help develop more innovative and more effective disease models and in turn help define specific patient sub-populations most likely to respond to new therapies,” said Dr. Stephen Friend, President of Sage Bionetworks.
“We continue to implement our partnering strategy as part of our larger mission to build a Commons where users can exploit the full potential of network analysis across multiple complex datasets,” Dr. Friend added. “Data and models from the collaboration will become available in the Sage repository one year following the completion of the project expanding the datasets publicly available.”
New Partnership to Provide Bioanalytical and DMPK ServicesNews
Concept Life Sciences, the integrated drug discovery, development and analytical services company, and Alderley Analytical, bioanalytical Contract Research Organisation (CRO), today announced they have signed a partnership agreement to provide high-value bioanalytical and DMPK study services.